Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246890 | 0.90 | SIGMAR1 (0.43) | SIGMAR1GRIN2BACHEPKML3MBTL1 | |
| SCHEMBL4245846 | 0.86 | MEN1 (0.40) | SIGMAR1GRIN2BACHEPKMKDM4E | |
| SCHEMBL4244829 | 0.81 | SIGMAR1 (0.41) | SIGMAR1GRIN2BACHECHRM2L3MBTL1 | |
| SCHEMBL4240896 | 0.80 | SIGMAR1 (0.40) | SIGMAR1GRIN2BACHEGAAKDM4E | |
| SCHEMBL4237510 | 0.77 | MEN1 (0.41) | SIGMAR1GRIN2BACHEL3MBTL1MEN1 | |
| SCHEMBL4240892 | 0.76 | SIGMAR1 (0.42) | SIGMAR1GRIN2BACHE | |
| SCHEMBL4241455 | 0.75 | SIGMAR1 (0.41) | SIGMAR1GRIN2BACHE | |
| SCHEMBL4240894 | 0.74 | CHRM2 (0.47) | SIGMAR1GRIN2BACHEPKMCHRM2 | |
| SCHEMBL4248307 | 0.73 | CHRM2 (0.52) | SIGMAR1ACHECHRM2CHRM1CHRM3 | |
| SCHEMBL4786764 | 0.73 | SIGMAR1 (0.43) | SIGMAR1GRIN2BL3MBTL1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | SIGMAR1 317/4885GRIN2B 421/4885ACHE 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.